RT Journal Article
SR Electronic
T1 Molecular Genetic Tumor Markers in Non-small Cell Lung Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1193
OP 1196
VO 25
IS 2B
A1 OYAMA, TSUNEHIRO
A1 OSAKI, TOSHIHIRO
A1 BABA, TETSURO
A1 NAGATA, YOSHIKA
A1 MIZUKAMI, MAKIKO
A1 SO, TETSUYA
A1 NAKATA, SHOJI
A1 ICHIKI, YOSHINOBU
A1 URAMOTO, HIDETAKA
A1 SUGAYA, MASAKAZU
A1 YOSHIMATSU, TAKASHI
A1 MORITA, MASARU
A1 HANAGIRI, TAKESHI
A1 SUGIO, KENJI
A1 KAWAMOTO, TOSHIHIRO
A1 YASUMOTO, KOSEI
YR 2005
UL http://ar.iiarjournals.org/content/25/2B/1193.abstract
AB Not only serum tumor markers, such as carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC) and carbohydrate antigen (CA) 125, but also serum growth factors have been examined to evaluate tumor stages and to predict the recurrence and metastasis in patients with non-small cell lung cancer (NSCLC) (1-5). In recent years, the analysis of the genome and proteome has advanced remarkably. An array of molecular genetic tumor markers (MGTMs) have been identified based on the biological characterization of tumors, such as tumor development, growth, invasion and metastasis. Molecular genetic tumor marker research has also entered a new era, since comprehensive gene profile analysis using cDNA microarrays and comprehensive protein expression analysis using proteomics technology have been developed. On the other hand, the frequency of lung cancer patients with which various tumor markers are associated is increasing in Japan (6-8). This paper reviews MGTMs characteristic of lung cancer and clarifies the clinical usefulness and applications of MGTM for cancer treatment. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved